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Abstract objectives Rates of first-line treatment failure and switches to second-line therapy are key
indicators for national HIV programmes. We assessed immunological treatment failure defined by
WHO criteria in the Tanzanian national HIV programme.
methods We included adults initiating first-line therapy in 2004–2011 with a pre-treatment CD4 count,
and ≥6-months of follow-up. We assessed subhazard ratios (SHR) for immunological treatment failure,
and subsequent switch to second-line therapy, using competing risks methods to account for deaths.
results Of 121 308 adults, 7% experienced immunological treatment failure, and 2% died without
observed immunological treatment failure, over a median 1.7 years. The 6-year cumulative
probability of immunological treatment failure was 19.0% (95% CI 18.5, 19.7) and of death, 5.1%
(4.8, 5.4). Immunological treatment failure predictors included earlier year of treatment initiation
(P < 0.001), initiation in lower level facilities (SHR = 2.23 [2.03, 2.45] for dispensaries vs. hospitals),
being male (1.27 [1.19, 1.33]) and initiation at low or high CD4 counts (for example, 1.78 [1.65,
1.92] and 5.33 [4.65, 6.10] for <50 and ≥500 vs. 200–349 cells/mm3, respectively). Of 7382
participants in the time-to-switch analysis, 6% switched and 5% died before switching. Four years
after immunological treatment failure, the cumulative probability of switching was 7.3% (6.6, 8.0)
and of death, 6.8% (6.0, 7.6). Those who immunologically failed in dispensaries, health centres and
government facilities were least likely to switch.
conclusions Immunological treatment failure rates and unmet need for second-line therapy are
high in Tanzania; virological monitoring, at least for persons with immunological treatment failure, is
required to minimise unnecessary switches to second-line therapy. Lower level government health
facilities need more support to reduce treatment failure rates and improve second-line therapy uptake
to sustain the benefits of increased coverage.
keywords adult, antiretroviral therapy, CD4 lymphocyte count, risk factors, Tanzania, treatment
failure
Introduction
The year 2012 saw the largest annual increase of HIV-
positive persons receiving antiretroviral therapy (ART),
with 9.7 million people in low- and middle-income coun-
tries on ART [1]. In 21 African countries with the highest
HIV burden, two-thirds of people in need of treatment in
2012 were receiving ART [1]. Furthermore, with recent
treatment guideline changes, the number of people eligi-
ble for first-line treatment will increase [2]. While much
remains to be done to reach all in need of treatment, the
focus has shifted to the implications of providing long-
term treatment for what, under the right care, has
become a chronic condition.
Monitoring persons on ART for treatment failure is
essential to ensure that their treatment remains potent
and to enable timely switches from first- to second-line
therapy. In South Africa, where routine viral load moni-
toring is performed, the proportion of persons switching
3–5 years after treatment initiation was approximately
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10% [3, 4], whereas in settings without routine viral load
monitoring, such as Malawi and Zambia prior to 2011,
switching rates were much lower (approximately 2% by
3 years) [4]. Delayed switching increases the risk of drug
resistance [5, 6] and subsequent higher viral load [7–9]
and hence impairs clinical outcomes [2], while early,
unnecessary switching may reduce treatment options and
increase costs. WHO recommends routine viral load
monitoring for persons on ART [2], but this remains too
expensive for resource-limited countries such as Tanza-
nia. In the absence of viral load monitoring, treatment
failure is diagnosed using immunological and clinical cri-
teria [2], as implemented in Tanzanian policy [10–12].
To date, there is a paucity of data on the rates and pre-
dictors of first-line treatment failure, and the use of sec-
ond-line therapy, within national programmes using
immunological and/or clinical criteria.
Tanzania had an estimated 1.3 million HIV-infected
adults in 2011 [13]. Of these, approximately 370 000
adults (28%) were enrolled in care, and approximately
260 000 were receiving ART, representing 65% in need
of treatment [13]. Our aim was to investigate the rate
and predictors of immunological treatment failure, and
subsequent switch to second-line therapy, among HIV-
infected adults receiving therapy through the Tanzania
government programme.
Methods
HIV care and treatment in Tanzania
The Tanzanian National AIDS Control Programme
(NACP) provides HIV prevention, care and treatment ser-
vices. In late 2003, the first HIV/AIDS Care and Treatment
Plan was launched, and free ART was rolled out from
2004. By the end of 2011, >1100 facilities were approved
to provide care and treatment services, estimated to enable
>1 million persons potentially to access ART [13].
HIV-positive persons enrolling in care and treatment
clinics are assessed for ART eligibility, defined pre-2012
(data collection period) as CD4 count <200 cells/mm3, or
CD4 count <350 cells/mm3 and WHO stage III, or WHO
stage IV regardless of CD4 count [10, 11]. Persons not
yet eligible for ART are encouraged to attend clinics six-
monthly for pre-treatment monitoring, while those on
treatment attend monthly. First-line treatment consists of
2 nucleoside/nucleotide-reverse transcriptase inhibitors
(NRTIs) and a non-NRTI, while second-line therapy
included 2 NRTIs plus a protease inhibitor. Individual
paper-based records, including unique, nationally attrib-
uted patient identifiers, are maintained at each facility,
and subsequently electronically entered by data entry
clerks before being regularly submitted to the national
database.
Study population
We included data from clinics reporting electronic, indi-
vidual-level data to the end of 2011. We included persons
who initiated first-line ART in 2004–2011 aged
≥15 years with a pre-ART CD4 count available and who
completed ≥6 months of follow-up.
Definition of immunological treatment failure
The Tanzanian 2005 National Guidelines for the Clinical
Management of HIV and AIDS defined immunological
treatment failure as CD4 count <30% of peak on-treat-
ment value or <pre-treatment levels [10]; this definition
was revised in 2009 to CD4 count <50% of peak value
within 6 months or <pre-treatment levels [11]. This
resembles the WHO 2010 Antiretroviral Therapy for
HIV Infection in Adults and Adolescents guidelines which
defined immunological treatment failure as CD4 count
<50% of peak value or <pre-treatment levels, or persis-
tently <100 cells/mm3 [14]; the WHO guidelines were
revised in 2013 to remove the criterion of a 50% drop
[2]. For this analysis, we used the WHO 2010 guidelines,
with a second consecutive confirmatory CD4 count for
the definition of immunological treatment failure, to rule
out transient drops in CD4 counts due to other infections
or measurement error. Immunological treatment failure
was only defined ≥6 months after treatment initiation [2].
We also considered a less strict definition of immunologi-
cal treatment failure, which did not require a confirma-
tory CD4 count (except for the criterion of CD4 count
<100 cells/mm3, as the WHO guidelines explicitly define
immunological treatment failure among individuals with
CD4 counts ‘persistently’ <100 cells/mm3).
Statistical methods
We assessed immunological treatment failure and death
rates and predictors using competing risks methods to
account for deaths. Death is a competing risk for immu-
nological treatment failure because its occurrence pre-
vents us from observing immunological treatment failure.
In such situations, standard Cox proportional hazards
models are not appropriate, and instead competing risks
models are required. Such models yield subhazards ratios
which, although statistically speaking are different, may
be interpreted in the same way as hazard ratios derived
from Cox models [15, 16]. Among those with
immunological treatment failure, we assessed switch to
2 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
F. M. Vanobberghen et al. HIV treatment failure and switch in Tanzania
second-line therapy, using similar methods. Loss to fol-
low-up was considered uninformative. Body mass index
(BMI) was not included in multivariable models, as it
was missing for approximately 70% of visits, mainly due
to missing height.
Data were censored at 31 December 2011. If a CD4
count was not recorded for >12 months, then follow-up
was censored at 12 months after the last CD4 count, but
that person could re-enter the risk set if another CD4
count was subsequently recorded. If the person reap-
peared with immunological treatment failure, then he/she
was considered to have immunologically failed at
12 months after the last CD4 count recorded before the
gap. Time-dependent variables at ART initiation or
switch were defined as the closest up to 3 months earlier,
and if none then up to 2 weeks after (except for CD4
count at treatment initiation, which permitted up to
4 weeks after, to allow for delayed reporting of CD4
counts). We performed a sensitivity analysis using 6
instead of 12 months for censoring follow-up. We per-
formed a second sensitivity analysis including only data
from 2009 or later (due to concerns about the changes in
ART provision, with more being provided by health cen-
tres and dispensaries in later years).
For the analysis of switch to second-line therapy, indi-
viduals who changed to an unknown ART regimen were
censored at that time; those with missing ART information
were considered to still be continuing on their first-line reg-
imen. Intermittent regimens of duration ≤14 days were
ignored. Individuals with missing ART information from
the date when they were last known to be on first-line ther-
apy until the date they switched to second-line therapy
were assumed to have switched at the mid-point between
these dates. Participants who changed therapy on the day
of immunological treatment failure were given 1 day of
follow-up. Analyses were conducted using Stata version 12
(StataCorp. 2011. Stata Statistical Software: Release 12.
College Station, TX: StataCorp LP). P-values are 2 sided.
Ethical considerations
This analysis was conducted on routinely collected data
under the auspices of the NACP and approved by the
London School of Hygiene & Tropical Medicine ethics
committee. Unique patient identifiers were used to pre-
serve anonymity, and all names and personal identifiers
were removed before analysis.
Results
In 348 clinics, 243 844 adults initiated first-line ART.
Of these, 71 285 (29%) participants did not have a
pre-treatment CD4 count recorded: 23 038 (32%) were
WHO stage IV (among whom treatment should have
been initiated regardless of CD4 count as per treatment
guidelines [10, 11]), but 5608 (8%) did not have WHO
stage recorded, and 26 599 (37%), 11 180 (16%) and
4860 (7%) were WHO stages I, II and III, respectively
(perhaps suggesting missing CD4 count data). Of the
remaining 172 559 participants, 11 397 (7%) died within
the first 6 months after treatment initiation, 13 625 (8%)
initiated treatment in the last 6 months of 2011 and
therefore had <6 months of follow-up, and 26 229
(15%) were lost to follow-up within 6 months; these par-
ticipants are excluded.
Of the remaining 121 308 participants (representing all
348 clinics), 73% initiated ART in hospitals and 67% initi-
ated in government-run facilities (Table 1). Two-thirds of
participants were female, 55% were married or cohabiting,
and 89% were working. A total of 26% of participants ini-
tiated ART with low BMI (<18.5 kg/m2), 16% with WHO
stage IV and 73% with low CD4 count (<200 cells/mm3).
The most common first-line ART regime was stavudine
based (61%), mainly driven by data from earlier years.
The use of zidovudine, lamivudine and nevirapine or efavi-
renz increased from 8% to 10%, respectively, in 2008, to
36% and 40%, respectively, in 2011, following the elimi-
nation of stavudine in 2010 (Table S1).
Nearly two-thirds of participants (65%) did not have
any gaps in their follow-up due to CD4 counts not being
recorded for >12 months; 28%, 6%, <1% and <1% of
participants had one, two, three or four such gaps in
their follow-up, respectively. Across all gaps, the median
gap length was 7 months, with an interquartile range of
3–13 months.
Immunological failure
Subsequent to the first 6 months on ART, 8384 (7%)
participants experienced immunological treatment failure
and 2486 (2%) died without immunological treatment
failure being observed, over a median of 1.7 years (maxi-
mum 8 years). Of those experiencing immunological
treatment failure, 1995 (24%) participants had CD4
counts <pre-treatment levels, 1400 (17%) <50% of on-
treatment peak, 2625 (31%) <100 cells/mm3, and 2364
(28%) had a combination of these components (Table
S2). The cumulative probability of immunological treat-
ment failure by 6 years (to when we had sufficient data
for reliable estimation) was 19.0% (95% CI: 18.5, 19.7)
and of death (without immunological treatment failure)
was 5.1% (4.8, 5.4; Figure 1).
Under the less strict immunological treatment failure
definition, 19 380 (16.0%) participants would have
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 3
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Table 1 Participant characteristics at ART initiation and immunological treatment failure
At ART initiation* At immunological failure*,†
N = 121 308 % N = 7382 %
Health facility level Hospital 87 770 72.7 4712 64.3
Health centre 16 798 13.9 1189 16.2
Dispensary 13 131 10.9 1027 14.0
Other‡ 2995 2.5 397 5.4
Health facility type Government 74 789 66.7 4696 68.8
Faith-based 28 343 25.3 1712 25.1
Private 8947 8.0 413 6.1
Year Up to end 2005 5951 4.9 42 0.6
2006 12 181 10.0 471 6.4
2007 19 770 16.3 954 12.9
2008 26 158 21.6 1396 18.9
2009 25 726 21.2 1559 21.1
2010 22 121 18.2 1581 21.4
2011 9401 7.7 1379 18.7
Sex Male 40 055 33.0 2630 35.6
Female 81 250 67.0 4752 64.4
Age, years 15 to 29 23 412 19.3 953 12.9
30 to 39 50 750 41.8 3063 41.5
40 to 49 31 848 26.3 2263 30.7
≥50 15 278 12.6 1099 14.9
Marital status§ Single 24 757 22.2 1648 25.2
Married or cohabiting 61 586 55.3 3493 53.4
Divorced or separated 11 866 10.7 635 9.7
Widowed 13 156 11.8 765 11.7
Functional status Working 102 301 88.7 6980 96.9
Ambulatory 11 866 10.3 177 2.5
Bed-ridden 1177 1.0 49 0.7
Weight, kg <45 21 754 18.1 690 9.4
45 to <55 47 019 39.1 2292 31.2
≥55 51 633 42.9 4365 59.4
BMI¶ Underweight 11 035 26.2 427 13.4
Normal 25 097 59.6 2030 63.7
Overweight 6002 14.2 732 23.0
WHO stage§ I 11 586 10.4 562 9.0
II 27 636 24.9 1445 23.0
III 53 603 48.3 3169 50.5
IV 18 158 16.4 1102 17.6
CD4 count, cells/mm3 <50 24 339 20.1 1822 24.7
50 to 199 64 753 53.4 3684 49.9
200 to 349 27 375 22.6 1333 18.1
350 to 499 3250 2.7 383 5.2
≥500 1591 1.3 158 2.1
First ART regimen§ Stavudine-based 73 402 60.5 5287 71.6
Zidovudine-based 46 739 38.5 2008 27.2
Other first line 1167 1.0 87 1.2
Time on first-line ART, years <1 2950 40.0
1 to <2 2475 33.5
≥2 1957 26.5
ART, antiretroviral therapy; BMI, body mass index.
*Values are number (% of those with non-missing data).
†Restricted to those included in the switching analysis (see main text).
‡‘Other’ facilities predominantly included institutional facilities with restricted access.
§At ART initiation (not updated at immunological failure; marital status only recorded at enrolment into care).
¶BMI categorised as underweight (<18.5 kg/m2), normal (18.5 to <25.0 kg/m2) or overweight (≥25 kg/m2).
4 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
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been considered to have experienced immunological
treatment failure, with cumulative probability of 23.8%
(23.5, 24.2) by 3 years and 40.6% (39.8, 41.5) by
6 years.
Predictors of immunological treatment failure
Using the definition of immunological treatment failure
with confirmatory CD4 count, in adjusted analyses, higher
risk of immunological treatment failure was found among
those who initiated treatment in lower level facilities and
in ‘other’ facilities, which predominantly included institu-
tional facilities with restricted access (P < 0.001; Table 2).
However, those in ‘other’ facilities had lowest death rate
(0.6 vs. 1.1/100 person-years in hospitals). The immuno-
logical treatment failure risk was lower in private vs. gov-
ernment facilities (subhazard ratio, SHR = 0.59 [95%
confidence interval, CI: 0.50, 0.69]), with no difference for
faith-based facilities (SHR = 1.01 [0.95, 1.07]). There was
lower immunological treatment failure risk with later year
of treatment initiation (P < 0.001), and death rates
decreased from 1.2/100 to 0.5/100 person-years among
those who initiated treatment pre-2006 and in 2011,
respectively. Females had lower immunological treatment
failure risk than men (SHR = 0.79 [0.75, 0.84]). Com-
pared to persons who were married or cohabiting at treat-
ment initiation, single persons were at higher
immunological treatment failure risk (SHR = 1.12 [1.05,
1.20]), but there was no evidence of a difference for those
divorced or separated, or widowed.
Persons initiating treatment with lower weight were at
somewhat higher risk of immunological treatment failure
(SHR = 1.07 [0.99, 1.16] and 1.08 [1.02, 1.14] for <45
and 45 to < 55 vs. ≥55 kg, respectively). There was some
difference in immunological treatment failure risk by
WHO stage at treatment initiation (P = 0.03), although no
clear trend across the stages. Of note, the competing risk of
death varied by stage (0.5 vs. 1.5/100 person-years for
WHO stage I and IV, respectively). Persons who initiated
with the lowest CD4 counts were at higher risk of immu-
nological treatment failure (SHR = 1.78 [1.65, 1.92] for
<50 vs. 200–349 cells/mm3). However, persons initiating
with high CD4 counts were also at higher immunological
treatment failure risk (SHR = 2.51 [2.20, 2.86] and 5.33
[4.65, 6.10] for 350–499 and ≥500 vs. 200–349 cells/mm3,
respectively). In the unadjusted model, persons who initi-
ated on zidovudine-based regimens had a lower immuno-
logical treatment failure risk vs. stavudine-based regimens;
this relationship was reversed once we adjusted for con-
founders (SHR = 1.14 [1.06, 1.21]). Persons who initiated
treatment with other regimens had much higher immuno-
logical treatment failure risk (SHR = 6.12 [4.90, 7.65] vs.
stavudine based). There was no evidence of a difference in
immunological treatment failure risk by age (P = 0.58) or
functional status (P = 0.21). Variable selection to obtain a
parsimonious model (removing variables in a stepwise
fashion with P > 0.05) yielded similar results to the full
model. Sensitivity analyses censoring follow-up after 6
rather than 12 months, or including only participants who
initiated in 2009 or later, yielded broadly similar results.
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Figure 1 Probability of immunological
treatment failure or death, following
initiation of first-line ART. ART,
antiretroviral therapy. Y-axis truncated at
0.3. Persons with <6 months of follow-up
(including due to death) were excluded
from the analyses. Immunological failure
was not defined until at least 6 months
after treatment initiation.
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Table 3 Rates and predictors of switching, after immunological treatment failure
Rate per 100
person-years
N
events Person-years
Subhazard ratio (95% confidence interval)
Univariable models Full multivariable model
Health facility level P < 0.001 P < 0.001
Hospital 2.7 315 11 462 1 1
Health centre 1.3 27 2075 0.42 0.29, 0.63 0.43 0.26, 0.71
Dispensary 1.1 21 1964 0.31 0.20, 0.48 0.50 0.27, 0.93
Other* 5.9 53 900 2.02 1.50, 2.71 2.27 1.52, 3.39
Health facility type P < 0.001 P < 0.001
Government 2.1 226 10 917 1 1
Faith-based 4.8 176 3667 2.26 1.86, 2.75 2.29 1.79, 2.91
Private 1.2 10 825 0.53 0.28, 0.99 † †
Year P = 0.004 P < 0.001
Up to end 2005 3.6 8 223 1.70 0.83, 3.49 1.08 0.35, 3.32
2006 1.8 39 2211 0.87 0.61, 1.26 1.21 0.76, 1.90
2007 2.0 75 3676 0.90 0.67, 1.21 1.25 0.88, 1.77
2008 2.7 111 4184 1 1
2009 3.0 100 3339 0.90 0.69, 1.19 0.86 0.62, 1.19
2010 2.4 52 2186 0.55 0.39, 0.76 0.47 0.31, 0.70
2011 4.7 31 666 0.65 0.43, 0.97 0.41 0.25, 0.65
Sex P = 0.005 P = 0.03
Male 3.1 174 5668 1 1
Female 2.2 242 10 818 0.76 0.62, 0.92 0.77 0.60, 0.97
Age, years P = 0.23 P = 0.76
15 to 29 3.0 67 2253 1.32 1.00, 1.76 1.07 0.75, 1.52
30 to 39 2.3 160 7003 1 1
40 to 49 2.5 123 4984 1.06 0.84, 1.34 0.94 0.72, 1.23
≥50 2.9 65 2231 1.19 0.89, 1.58 0.86 0.61, 1.23
Marital status‡ P = 0.21 P = 0.35
Single 2.9 102 3483 1.20 0.94, 1.53 1.21 0.93, 1.59
Married or cohabiting 2.4 180 7442 1 1
Divorced or separated 2.0 27 1349 0.83 0.55, 1.25 0.92 0.60, 1.42
Widowed 2.8 48 1698 1.20 0.87, 1.65 1.24 0.87, 1.75
Functional status P = 0.43 P = 0.34
Working 2.6 394 15 126 1 1
Ambulatory 1.6 7 439 0.64 0.30, 1.35 0.50 0.20, 1.26
Bed-ridden 1.6 2 123 0.67 0.16, 2.74 0.94 0.22, 4.08
Weight, kg P = 0.92 P = 0.54
<45 2.7 39 1446 0.99 0.71, 1.39 1.05 0.70, 1.59
45 to <55 2.5 124 4939 0.96 0.77, 1.19 0.87 0.67, 1.14
≥55 2.5 253 10 058 1 1
WHO stage‡ P < 0.001 P < 0.001
I 4.2 51 1201 1.73 1.27, 2.37 1.64 1.18, 2.28
II 3.0 86 2867 1.16 0.89, 1.50 1.11 0.84, 1.47
III 2.5 171 6882 1 1
IV 1.6 37 2288 0.63 0.44, 0.89 0.56 0.38, 0.81
CD4 count, cells/mm3 P < 0.001 P < 0.001
<50 2.9 115 3975 2.16 1.51, 3.11 6.33 4.03, 9.95
50 to 199 3.0 255 8543 2.31 1.65, 3.23 3.70 2.42, 5.67
200 to 349 1.3 39 2927 1 1
≥350 0.7 7 1041 0.48 0.21, 1.06 0.52 0.20, 1.36
First ART regimen‡ P = 0.07 P < 0.001
Stavudine-based 2.3 301 13 018 1 1
Zidovudine-based 3.4 115 3414 1.22 0.99, 1.52 1.76 1.36, 2.29
Other first line 0 0 55 § §
8 © 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd.
Tropical Medicine and International Health volume 00 no 00
F. M. Vanobberghen et al. HIV treatment failure and switch in Tanzania
Switch to second-line therapy
Of 8384 persons who immunologically failed on first-line
therapy, 135 (2%) had previously used second-line ther-
apy, 276 (3%) had previously taken an unknown regimen,
and 591 (7%) had an immunological treatment failure date
estimated at 12 months after the last CD4 count before a
gap of >12 months; these persons are excluded from the
following analyses. Of the remaining 7382 (88%) partici-
pants, 40% had been on first-line ART for <1 year, 34%
for 1 to <2 years and 27% for ≥2 years (Table 1). The dis-
tribution of participant characteristics at the time of immu-
nological treatment failure broadly reflected those at ART
initiation. The proportions of participants with CD4
counts of <50, 50–199, 200–349, 350–499 and ≥500 cells/
mm3 at immunological treatment failure were 25%, 50%,
18%, 5% and 2%, respectively.
Overall, 416 (6%) persons were observed to subse-
quently switch to second-line therapy, while 355 (5%)
died before switching. By 4 years after immunological
treatment failure, the cumulative probability of switching
was 7.3% (95% CI: 6.6, 8.0) and of death 6.8% (6.0,
7.6; Figure 2).
The most common second-line regimen to which peo-
ple switched was abacavir, didanosine and ritonavir-
boosted lopinavir (n = 343; 82%), followed by tenofovir,
emtricitabine and ritonavir-boosted lopinavir (43; 10%).
The reasons for switch were not reported for 162 (39%)
individuals; of those given, the most common reasons
were immunological treatment failure (184; 72%) or clin-
ical treatment failure (20; 8%).
Predictors of switch to second-line therapy
In adjusted analyses, there were large differences in the
switching rates by facility level and type, with those who
immunologically failed in health centres and dispensaries
being less likely to switch than those in hospitals
(SHR = 0.43 [95% CI: 0.26, 0.71] and 0.50 [0.27, 0.93],
respectively), and those in ‘other’ facilities more likely to
switch (SHR = 2.27 [1.52, 3.39]). People who experi-
enced immunological treatment failure in faith-based
facilities were much more likely to switch than those in
government facilities (SHR = 2.29 [1.79, 2.91]). We
observed less frequent switching with later year of immu-
nological treatment failure (P < 0.001). Women were less
likely to switch than men (SHR = 0.77 [0.60, 0.97]). Per-
sons at lower WHO stage at treatment initiation were
more likely to switch (P < 0.001; for example,
SHR = 1.64 [1.18, 2.28] for WHO stage I vs. III). Per-
sons with lower CD4 count at immunological treatment
failure were much more likely to switch (P < 0.001; for
example, SHR = 6.33 [4.03, 9.95] for <50 vs. 200–349
cells/mm3). Persons who had initiated ART on zidovu-
dine-based therapy were more likely to switch than those
on stavudine-based regimens (SHR = 1.76 [1.36, 2.29]).
There was increasing probability of switch with increas-
ing time on therapy (P < 0.001). There was no evidence
of a difference in switching rates by age (P = 0.76), mari-
tal status (P = 0.35), functional status (P = 0.34) or
weight (P = 0.54).
Discussion
In this study of >120 000 HIV-infected adults initiating
first-line therapy in Tanzania, the need for second-line
therapy was high, with immunological treatment failure
rates of 19% by 6 years after treatment initiation. The
analysis was restricted to persons with ≥6 months of fol-
low-up, excluding the 7% of people who died within
6 months; nonetheless, over the following 6 years, there
was a 5% cumulative probability of death without
observed immunological treatment failure. After
Table 3 (Continued)
Rate per 100
person-years
N
events Person-years
Subhazard ratio (95% confidence interval)
Univariable models Full multivariable model
Time on first-line ART, years P < 0.001 P < 0.001
<1 1.2 101 8378 1 1
1 to <2 2.9 155 5433 2.12 1.65, 2.72 2.34 1.72, 3.17
≥2 6.0 160 2674 3.58 2.80, 4.58 5.34 3.84, 7.44
ART, antiretroviral therapy.
‘1’ indicates the reference category.
*‘Other’ facilities predominantly included institutional facilities with restricted access.
†Not reliably estimable as few switches to second-line therapy, therefore omitted this category from the model.
‡At ART initiation rather than immunological failure (marital status only recorded at CTC enrolment).
§Omitted from the model as no one in this category was observed to switch to second-line therapy.
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 9
Tropical Medicine and International Health volume 00 no 00
F. M. Vanobberghen et al. HIV treatment failure and switch in Tanzania
immunological treatment failure, the cumulative proba-
bility over 4 years of switching to second-line therapy
was 7%, which was approximately the same as that of
death (7%).
To our knowledge, this is the first study to assess
immunological treatment failure rates and switches to
second-line therapy among adults on first-line ART using
national routinely collected data. In a recent study from
Nigeria, which used the same WHO criteria for immuno-
logical treatment failure but without a confirmatory CD4
count, the cumulative probability of immunological treat-
ment failure was approximately 35% by 3 years, similar
to our estimation of 24% under the less strict immuno-
logical treatment failure definition [17]. When a confir-
matory CD4 count was incorporated in the Nigerian
analysis, the overall proportion of participants experienc-
ing immunological treatment failure reduced from 32%
to 10% and therefore the cumulative immunological
treatment failure probability when incorporating a confir-
matory CD4 count (not directly reported) is likely to be
similar to that observed under the main immunological
treatment failure definition in our study. The differences
in the estimated immunological treatment failure rates
between definitions requiring and not requiring a confir-
matory CD4 count are large. CD4 count measurement is
known to have large variability and CD4 count trajecto-
ries may display transient changes; thus, we believe that
it is unlikely that the immunological treatment failure
rates are as high as suggested by the unconfirmed criteria,
hence reinforcing the importance of a confirmatory CD4
count, which is typically what clinicians seek in practice.
Encouragingly, immunological treatment failure rates
dropped with later calendar year of ART initiation, with
72% lower risk among those who initiated in 2011 vs.
2008, which may be attributable to improvements in care
and drug efficacy. Switching rates also decreased over
time, with 59% lower ‘risk’ of switching among those
who immunologically failed in 2011 vs. 2008, perhaps
suggesting that the national programme in Tanzania has
not yet organised itself for widespread second-line ther-
apy use. The overall low switching rates observed in this
study indicate that there is a large unmet need for sec-
ond-line therapy, and so this should be a future priority
for the ART programme if excess morbidity and mortal-
ity among persons on ART are to be minimised. Our
results likely reflect what clinicians are doing in practice,
regardless of national policies, due to barriers in access-
ing second-line therapy such as lack of availability and
higher cost. Approaches to increase coverage to ART,
such as decentralisation, could be harnessed to increase
access to second-line therapy.
We found important differences in the rates of both
immunological treatment failure and switching by the
types of facilities participants were attending. The Tanza-
nian HIV programme has successfully devolved care to
lower level clinics, and there are calls for similar initia-
tives for the management of other chronic diseases [18].
However, the higher immunological treatment failure
rates and lower switching rates in lower level and partic-
ularly government-owned facilities highlight that ade-
quate training and support is required for front-line
healthcare workers, along with a stable drug supply chain
0
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Figure 2 Probability of switch from first-
to second-line ART or death, following
immunological treatment failure. ART,
antiretroviral therapy. Y-axis truncated at
0.3. Participants who changed therapy on
the day of immunological failure were
given 1 day of follow-up, so that they
were included in the time-to-event
analyses.
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and adequate equipment, to ensure that consistent ser-
vices are provided.
We identified key subgroups of the population who may
be at higher immunological treatment failure risk including
men, single persons, and those with lower weight at ART
initiation. Men typically have poorer healthcare-seeking
behaviours than women, as illustrated by mean lower CD4
counts at enrolment to HIV care [5, 13], poorer ART
uptake [19], and the higher immunological treatment fail-
ure risk observed in this study. In contrast, we found that
women were less likely to switch to second-line therapy
than men; the reasons for this are unclear and this finding
warrants further investigation. The drivers behind the
higher immunological treatment failure risk with zidovu-
dine-based and other first-line regimens, compared to
stavudine-based therapy, are unclear. Stavudine has been
phased out since 2010, and tenofovir-based regimens are
now recommended. Although only a small percentage of
participants initiated tenofovir in this cohort, its use is
increasing. Both low and high CD4 counts at ART initia-
tion were associated with higher immunological treatment
failure risk. Participants starting treatment with CD4
counts <100 cells/mm3 would have met the definition for
immunological treatment failure if they had two subse-
quent CD4 counts <100 cells/mm3, even if higher than
their baseline value. Individuals initiating treatment at high
CD4 counts were likely to be different in some way; for
example, they may be presenting for care due to an oppor-
tunistic infection. While we have controlled for the con-
founders routinely captured in the national data, such as
WHO stage, there may remain residual confounding.
Lower CD4 count at immunological treatment failure
was strongly associated with switching; nonetheless, our
results indicate that there remains a large need for sec-
ond-line therapy which is not being met, with the proba-
bility of switch among those who have immunologically
failed being only 7% by 4 years. The poor predictive
ability of immunological treatment failure for virological
failure is well known [17, 20–24], meaning that persons
with a low CD4 count may not necessarily have virologi-
cally failed. However, in a setting without routine or tar-
geted viral load monitoring, switching decisions must be
made based on the immunological evidence [2], and this
is the situation in many countries across sub-Saharan
Africa. New and cheaper viral load tests, using dried
blood spots, would ideally be used to perform targeted
monitoring of persons with immunological treatment fail-
ure to minimise unnecessary switches to second-line treat-
ment, as recommended by the WHO [25]. Switching
persons who have immunological treatment failure, but
not virological failure has individual and economic impli-
cations, and such persons would be unlikely to benefit
from second-line therapy, and therefore, it would be
important to assess viral load before switch.
A strength of this study is the use of appropriate statis-
tical methods, namely competing risks analysis, to take
into account the correlation between death and immuno-
logical treatment failure. A na€ıve approach would be to
use proportional hazards regression, ignoring the compet-
ing risk of death for immunological treatment failure.
Such an approach underestimates the immunological
treatment failure rate, due to deaths occurring in those
with unobserved immunological treatment failure. This
underestimation may be greater in a resource-poor setting
with less-intensive CD4 monitoring. In addition, our
results were robust to sensitivity analyses.
While we included over 120 000 persons in this analy-
sis, the 348 clinics included do not represent every region
in Tanzania, as the analysis was restricted to clinics who
submitted electronic data in 2011. Due to the definition
of immunological treatment failure, we were not able to
include nearly a third of registered participants as they
did not have a baseline CD4 count; it is difficult to know
whether this selection has led to bias in our results. Attri-
tion rates from care and treatment clinics in Tanzania are
high [26], and it is likely that many deaths remain unre-
ported; therefore, our mortality rates will be underesti-
mates. While we attempted to address incompleteness of
immunological data by censoring follow-up when no
CD4 count had been recorded for >12 months, it may be
that incomplete data contribute to the deaths without
immunological treatment failure. Information on causes
of death might help inform this question further, but
these data are not currently captured. We used the WHO
2010 immunological treatment failure criteria, covering
the majority of the data collection period [14]; applica-
tion of the WHO 2013 guidelines would yield lower
immunological treatment failure rates [2]. The implica-
tions of different definitions could be explored, including
the incorporation of persons who initiated at WHO stage
IV without CD4 measurements recorded. Further, inter-
pretations of immunological treatment failure were
required for analysis, for example related to ‘persistent’
CD4 count <100 cells/mm3. This raises questions about
how the guidelines are interpreted in clinical practice.
The guidelines state that transient drops in CD4 count
should be ignored, and we attempted to address this by
requiring a confirmatory CD4 count for immunological
treatment failure, but we may therefore have underesti-
mated the immunological treatment failure rate. How-
ever, the immunological treatment failure rates indicated
by our less strict definition, which did not require a con-
firmatory CD4 count, were implausibly high. Detailed
information on clinical treatment failure was not
© 2015 The Authors. Tropical Medicine & International Health Published by John Wiley & Sons Ltd. 11
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captured, although the number of persons switching to
second-line therapy in the absence of immunological
treatment failure was low, suggesting perhaps that clini-
cal failure – which may be more complex to diagnose –
may not be adequately assessed in clinics. This study does
not attempt to address the optimal time-to-switch to sec-
ond-line therapy to minimise adverse outcomes, which is
of importance and should be considered for future work.
As second-line therapy use increases, work should address
outcomes after switch, particularly as a substantial pro-
portion of persons may be expected not to achieve viro-
logical suppression [7, 27].
In summary, we used national routinely collected data
to investigate immunological treatment failure rates in
Tanzania; such rates are high, and the need for second-
line treatment is not being met. The Tanzanian national
control programme has successfully focused on ART roll-
out, and this remains crucial, particularly with new
WHO guidelines recommending earlier initiation [2]. To
sustain the benefits of increased coverage, there is a prior-
ity to address the need for second-line therapy, and (tar-
geted) virological monitoring is required to minimise
unnecessary switches to second-line therapy.
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